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Promotion of metastasis by a specific complex of coagulation factors
may be independent of fibrin formation
P. McCulloch & W.D. George
University Department of Surgery, Western Infirmary, Glasgow, UK.
Summary Coumarins inhibit metastasis in a number of animal models, but the mechanism of this effect
remains unclear. We have investigated the relationship between the coagulation system and metastasis using a
new model system, involving i.v. injection of Mtln3 rat mammary carcinoma cells into Fischer 344 rats, and
subsequent estimation of pulmonary seeding.
Injection of factors II, VII, IX and X elevated the median number of surface pulmonary seedlings per
animal to 182, and injection of factors II, IX and X to 181, compared with a median for control animals of
12 (P<0.001). Injection of factor VII alone, or of bovine serum albumin did not significantly affect
pulmonary seeding. In a second experiment, arvin defibrination reduced the mean plasma fibrinogen
concentration to 76.8mgdl-1 from a control value of 228mgdl-1. This degree of defibrination had no
significant effects on pulmonary seeding, nor on the enhancing effects of factor complex injection (median
numbers of seedlings per animal; control 15, arvin 21, arvin plus factors II, VII, IX and X 170, factors II,
VII, IX and X only, 157). Factor complex injections did not detectably shorten thrombotest clotting times. In
vitro testing suggested that Mtln3 cells contain little or no conventional factor X activating cancer
procoagulant.
The complex of coagulation factors II, IX and X appears to contain a component which greatly enhances
metastasis in this model. This may explain the previously reported antimetastatic effect of coumarin
anticoagulants, which suppress factors II, VII, IX and X. The enhancing effect of the factor complex does not
appear to be altered by significant reductions in fibrin forming capacity, and defibrination itself has no effect
on metastasis. These findings suggest the possibility that the effect of this factor complex on metastasis may
be mediated via mechanisms other than the formation of a fibrin clot.
There is extensive evidence from both clinical and experi-
mental studies for an interaction between the coagulation
system and the spread and growth of malignant disease
(Wood, 1958; O'Meara, 1968; Hilgard et al., 1977; Zacharski
et al., 1979; Dvorak et al., 1981). Patient studies have
demonstrated the existence of marked subclinical distur-
bances of the coagulation system in nearly all cancer patients
(Sun et al., 1979; Rickles & Edwards, 1983; Mannuci et al.,
1985), whilst animal experiments have suggested that the
coagulation system may play an important role in the
pathogenesis of blood borne metastasis (Koike, 1964;
Agostino et al., 1966; Brown, 1973; Wood, 1974; Poggi et
al., 1978). The most striking and consistent finding in such
animal experimentation has been the antimetastatic effect of
the coumarin group of anticoagulant drugs in a variety of
tumour/host combinations (Ryan et al., 1969; Hilgard &
Maat, 1979; Williamson et al., 1980). The coumarins mediate
their anticoagulant activity by antagonising the action of
vitamin K, an essential cofactor in the hepatic synthesis of
the coagulation factors II (prothrombin), VII, IX and X
(Stenflo & Suttie, 1977). We have demonstrated that war-
farin, a member of the coumarin group, inhibits metastasis
in a model system comprising the Mtln3 rat mammary
carcinoma clone and the syngeneic Fischer 344 rat, both
when intravenous injection of the cells is employed and in
the more realistic model involving spontaneous metastasis
(McCulloch & George, 1987). In addition, we showed that
warfarin has no important cytotoxic effects for these tumour
cells, that it inhibits metastasis principally by its effects on
the host animal, and that the inhibition of metastasis is
reversed by replenishment of the coagulation factors which
warfarin suppresses. The exact role of these factors in the
metastatic process therefore merited further study. The
present studies were designed to determine whether the
previously studied factor complex, or parts of it, could
enhance metastasis in normal rats, and if so, whether this
enhancing effect was dependent on a normal capacity to
form fibrin.
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Animals and methods
Animals
Female Fischer 344 rats (Olac Limited, Bicester, UK), 6-8
weeks old, mean weight 140g, were used in all experiments.
Animals were fed a standard laboratory diet (CRM diet,
Labsure, Cambridge, UK) and tap water with a chlorine
content of 7 mg -1. All animals were healthy according to
visual observations, and to the results of routine micro-
biological testing for infection.
Tumour cells
The tumour cells were a clone of rat mammary carcinoma
designated Mtln3, originally derived by Neri and Nicolson
(Neri et al., 1982) from the 7,12-dimethylbenz(a)anthracene-
induced adenocarcinoma 13762 (Segaloff, 1966). Cells were
cultured in 75 cm2 tissue culture flasks (Gibco, Paisley, UK)
in equal parts of Hams' FIO and Dulbecco's modified
Eagles' Medium (FIO/DMEM), with 10% foetal calf serum
(FCS) but without antibiotics. Cultures were maintained at
37°C in equilibrium with 2% Co2 in air. Subconfluent
cultures were passaged by the use of Ca2+ and Mg2+ free
PBS followed by 0.25% Trypsin (Gibco, Paisley, UK).
Subculture was performed by adding 3 x 106 viable cells to
further 75 cm2 flasks. Cells were passaged a maximum of six
times between thawing and use, to minimise problems of
phenotypic drift (Neri & Nicolson, 1981). Multiple subcul-
tures of the cell line were stored in liquid nitrogen at
- 196°C, and fresh cultures were begun from these as
required. Inocula of 106 cells from stock cultures injected
into the mammary fat pad of Fischer rats at the beginning
and at the end of this series of experiments showed no
change in the metastatic potential of the line.
Coagulation factor preparations
A heat treated concentrate of human coagulation factors II,
IX and X, prepared from pooled plasma by crypoprecipi-
tation and supernatant adsorption with DEAE cellulose, was
obtained from Dr R.J. Perry of the Protein Fractionation
Centre, Edinburgh, UK. A heat treated concentrate of
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human factor VII, prepared by a similar procedure using
DEAE sepharose, was obtained from Dr J.K. Smith of the
Protein Fractionation Centre, Churchill Hospital, Oxford,
UK. The factors were administered according to a regimen
which had been shown in previous experiments to reconsti-
tute coagulation in the fully warfarinised rat for 12 h
(McCulloch & George, 1987). Each rat was given a dose
representing 6 units of factors II and X, 7 units of factor IX
and 10 units of factor VII at the time of tumour cell
injection, and the dose was repeated after 6 h. The fluid
volume of the factor injections totalled 0.6 ml. One unit is
sufficient to restore 1 ml of completely depleted human
plasma to normal activity for the factor concerned.
Experimental model of metastasis
The model of metastasis used involved intravenous injection
of Mtln3 tumour cells into F344 rats, with subsequent
sacrifice and examination of the lungs for tumour seeding.
Mtln3 cells were prepared from subconfluent cultures as
described above, then washed twice by centrifugation for
5min at 200g in F10/DMEM with FCS, and a third time in
FI0/DMEM alone. After resuspension in F10/DMEM, cell
density was assessed using a Coulter model ZB cell counter,
and viability by Trypan Blue exclusion. All cultures used
were >90% viable. An injection of 0.2 ml of this cell
suspension was made into the lateral tail vein of F344 rats
under light ether anaesthesia. Rats were maintained on
normal diet and water for 17 days, then killed by cervical
dislocation. Full autopsy was performed on all animals, and
any tissue suspected of containing tumour deposits was
submitted to histological examination. The lungs were
prepared for assessment of pulmonary seeding by the
method of Wexler (1966). This entails inflation of the lungs
via the trachea with a 15% solution of india ink, followed by
fixation in Fekete's solution for at least 48h. Surface
pulmonary tumour nodules can then be identified and
counted accurately. All specimens were counted on two
occasions by a single observer, who was unaware of the
treatment given.
Experiment 1: Enhancement of metastasis by
coagulation factors
Five groups of 10 F344 female rats, 6-8 weeks old, were
used. All animals were injected intravenously with 104 Mtln3
cells as described above. At the same time, additional
treatments were begun as follows:
Group A: These control animals received no form of treat-
ment other than tumour cell injection.
Group B: These animals received two i.v. injections of a
complex of the coagulation factors II, VII, IX
and X, as described above.
Group C: These animals received two i.v. injections of factor
VII alone.
Group D: These animals received two i.v. injections of the
complex of factors II, IX and X, but not factor
VII.
Group E: These animals received two i.v. injections of
bovine serum albumin (Sigma, Poole, UK).
No animal received treatment with warfarin or any other
anticoagulant. In all groups receiving some form of treat-
ment (Groups B-E) the first intravenous injection was given
at the same time as the tumour cells, and the second 6 h
later. The dose of bovine serum albumin used was 30mg in
0.6ml of F10/DMEM; this gave the same protein concen-
tration as the factor complex injection in Group B rats.
Bovine serum albumin and factor complex preparations were
passed through a 0.2,um filter before injection, for steriliza-
tion and removal of any potentially embolic material. Com-
parison of the numbers of seedlings per set of lungs in the
different groups was performed by Mann-Whitney U test.
Experiment 2: Role offibrin formation in
enhancement of metastasis
Four groups of 10 Fischer 344 female rats, 6-8 weeks old,
were used. All animals were injected i.v. with 104 Mtln3 cells
as described above. At the same time, additional treatments
were begun as follows:
Group A: These control animals received no form of treat-
ment other than tumour cel-l injection.
Group B: These animals received two i.v. injections of a
complex of the factors II, VII, IX and X.
Group C: These animals received factor complex injections
in the same way as group B animals, but received
additional treatment before and at the time of
tumour cell injection with arvin.
Group D: These animals received treatment with arvin
according to the same protocol as group C
animals, but did not receive any factor complex
injections.
Factor complex injections were given as in experiment l.
Arvin was given i.v. in a dose of 150unitskg-1, 6h before,
and s.c. in the same dose 6 h after injection of tumour cells.
The arvin solution was filtered in the same way as the factor
complex injections. Sacrifice, autopsy and estimation of
pulmonary metastasis was performed exactly as in experi-
ment 1.
Monitoring of coagulation system activity
The effects of the various treatments on coagulation were
monitored by performing thrombotest (Nyegaard, Oslo,
Norway) estimations on 3 animals per group immediately
after the first injection. Tail vein blood (50,l) was used for
the assay. In experiment 2 the effects of arvin treatment were
monitored by measurement of plasma fibrinogen concen-
tration in samples of tail vein blood at the time of tumour
cell injection and again 12 h later. Fibrinogen was measured
by the method of Clauss (1957), on 0.3ml plasma samples.
Thrombotest and fibrinogen values in different groups were
compared where appropriate using the t test.
Analysis ofprocoagulant activity of tumour cells
Mtln3 cells were trypsinised and washed in F10/DMEM as
described above, resuspended in FIO/DMEM (without FCS),
counted and adjusted to a cell density of 8 x 106 ml. This
suspension (0.1 ml) was added to 0.1 ml of citrated plasma
and 0.1 ml of CaCl2 (0.25 M) at 37°C and the clotting time of
the mixture recorded electronically using a Dade fibrometer.
The procedure was carried out in triplicate with normal
human plasma and with bovine plasma deficient in factor
VII (factor VII DBP) and in both factors VII and X (factor
VII and XDBP). Mtln3 cells were compared with two non-
neoplastic cell lines. 3T3 (untransformed mouse fibroblast)
cells and MDCK (neonatal dog kidney) cells, and with
Mtln3 cells exposed for 72 h in vitro to a 10pM concen-
tration of warfarin.
Results
Experiment 1: Enhancement of metastasis by
coagulation factors
The median number of pulmonary seedlings and semi-
interquartile range are recorded for each group in Table I. In
the control group (group A), the median number of seedlings
per animal was 13, and this was not significantly affected by
treatment with factor VII alone (group C, median 11) or
with bovine serum albumin (group E, median 23). Treatment
with the entire factor complex, or with the component
comprising factors II, IX and X produced many more
seedlings; the median was 182 in group B and 181 in group
D. These results were both very significantly greater than160 P. McCULLOCH & W.D. GEORGE
Table I Experiment 1: Number of pulmonary tumour seedlings per
animal
Group A Group B Group C Group D Group E
Median 13 182a 11 181a 23
Semi-
interquartile
range 5-15 84->200 7-25 138->200 13-26
Accurate estimes of tumour numbers were not attempted in
animals with over 200 lung seedlings. aIndicates P<0.001 on com-
parison of group results with control group by Mann-Whitney
U test.
that for control animals (P<0.001), but were not signifi-
cantly different from each other.
Experiment 2: Role offibrin formation in enhancement
of metastasis
The median number of pulmonary seedlings, and the semi-
interquartile range for each group are given in Table II. In
the control group (group A), the median was 15 tumour
deposits per animal; the result for animals treated with arvin
alone (group D) was 21 tumours per animal, which was not
significantly different from this. As in experiment 1, injection
of coagulation factors II, VII, IX and X (group B) enhanced
metastasis very markedly, in this case to 157 tumours per
animal. Group C animals, which received both arvin and
coagulation factor treatment, also showed a very marked
enhancement of tumour seeding, to 170 tumours per animal.
Both group B and group C, therefore, show a highly
significant enhancement of metastasis when compared with
the control group (P<0.01). The difference between groups
B and C themselves was not significant (P<0.92).
Monitoring of coagulation system activity
The mean thrombotest time for untreated rats in this
experiment was 28 sec (range 26-31); rats treated with coagu-
lation factors had a mean of 25 sec (range 25-26), and those
treated with arvin a mean of 30.7 sec (range 29-32). Neither
of these results was significantly different from that of
normal rats. Rats treated with both arvin and coagulation
factors (group C) had a mean thrombotest time of 28.5 sec
(range 27-30). Arvin, therefore, did not significantly lengthen
the thrombotest time, nor did coagulation factor injections
significantly shorten it. The mean plasma fibrinogen concen-
tration in control animals was 228.7 mgdl-1 (s.d.
16.5mgdl-1). In arvin treated animals the mean value was
76.8 mgdl - (s.d. 18.8 mgdl-1) at the time of tumour cell
injection, rising to 116.3 mgdl-1 12 h later (s.d. 20.2). Arvin
was therefore effective in reducing the plasma fibrinogen
concentration to one-third of the normal at tumour cell
injection, and in maintaining a substantial reduction for at
least 12 h thereafter.
Procoagulant activity of tumour cells
All three cell lines promoted coagulation in this assay. The
Table II Experiment 2: Number of pulmonary tumour seedlings per
animal
Group A Group B Group C Group D
Median 15 157a 170a 21
Semi-interquartile
range 9-27 106-198 75->200 13-47
Table III Procoagulant activity of Mtln3, MDCK and 3T3 cells
Factor Factor
VII DBP VII and X DBP
Mtln3 147 >500
Mtln3 (warfarin treated) 133 >500
MDCK 182 294
3T3 152 367
clotting time in the presence of Mtln3 cells was significantly
prolonged in factor VII DPB compared with normal plasma,
whilst no clotting occurred in factors VII and X DBP.
Similar results were recorded for MDCK and 3T3 cells. Pre-
incubation of Mtln3 cells in lOuM warfarin did not affect
their ability to promote coagulation of normal or factor
deficient plasmas (Table III).
Activities are expressed as a percentage of the clotting
time obtained using pooled normal human plasma. Results
represent the mean of triplicate assays performed on at least
two occasions. Within assay variation was < 10%.
Discussion
The experiments described in this paper demonstrate con-
trasting effects on metastasis of two different manipulations
of the coagulation system. In order to interpret the results
correctly, it is important to understand clearly the effect on
coagulation of the treatments used.
The injection of an excess of coagulation factors into
animals whose coagulation was already optimal did not
appear to produce excessive or supranormal coagulation, as
measured by thrombotest estimation. This result demon-
strated that the preparations used had no significant content
of activated factors. It is therefore unlikely that the
striking effect of factor complex injections on metastasis can
be explained by a major effect on the activity of the
coagulation system.
Arvin removes fibrinogen from the circulation by cleaving
fibrinopeptide A from the molecule; this produces an inac-
tive monomer, des-A-fibrinogen, which is rapidly cleared by
the reticuloendothelial and fibrinolytic systems (Bell et al.,
1978). Arvin effectively reduced plasma fibrinogen concen-
tration of our animals by nearly 70% at the time of tumour
cell injection. This is roughly equivalent to a reduction of
fibrin forming capacity of the same amount. The dose used
was chosen to avoid causing any significant circulatory
disturbance. Preliminary experiments showed that rats could
tolerate very high doses of arvin, but that above
300 IUkg-1, significant toxic effects could be observed
during i.v. injection. Half of this dose was therefore used in
the present experiment. The level of defibrination achieved
was similar to the target range in humans when the drug is
used clinically as an anticoagulant.
The results of our two experiments can now be summar-
ised. First, injection of the coagulation factors II, VII, IX
and X into normal rats greatly enhances the metastasis of
tumour cells injected at the same time; second, this effect
persists if factor VII is omitted from the complex, whilst this
factor alone has no discernible effect=on metastasis. Third, a
very significant reduction in fibrin forming capacity has no
discernible effect on metastasis. Finally, this degree of reduc-
tion in fibrin forming capacity does not diminish the enhanc-
ing effect on metastasis of the II, VII, IX and X factor
complex. These findings indicate that some component of
the II, IX and X complex is capable of greatly enhancing
metastasis. They also suggest that this enhancing effect may
not be dependent on the formation of fibrin. These
conclusions are consistent with the results of our previous
studies, and with reports (Hagmar, 1972; Donati et al.,
1978), that defibrinating agents have no consistent effect on
metastasis in other models.
bne animal in group B and two animals in group C died from the
effects of repeated ether anaesthesia. The results in these two groups
are therefore calculated on 9 and 8 animals respectively. aIndicates
P<0.01 (Mann-Whitney U test for group results against control
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Complete defibrination cannot be achieved with arvin in
this model, and it is therefore possible that enough fibrin
remains after arvin treatment to fulfil a vital role in enhanc-
ing metastasis. However the very marked reduction in meta-
stasis achieved with coumarin anticoagulant treatment (Ryan
et al., 1969; Brown, 1973; Hilgard et al., 1978; Poggi et al.,
1978; McCulloch & George, 1987) is in striking contrast with
the complete absence of any such reduction following arvin
treatment. If the formation of a fibrin clot is essential to the
metastasis-enhancing process, it is surprising that two major
suppressive influences on coagulation should have such
contrasting results. Conversely, the marked enhancement of
metastasis achieved in normal animals by injecting coagula-
tion factors is unlikely to be due to enhanced coagulation
activity, since this could not be detected. Further work is
required to confirm our findings, but the evidence of these
studies is in favour of a potentiating mechanism which
involves specific coagulation factors, rather than coagulation
as a whole.
Certain tumour cells have been shown to produce a
vitamin K dependent cysteine protease procoagulant (CP)
which directly activates factor X (Gordon et al., 1975), and
which may be implicated in the process of metastasis (Col-
ucci et al., 1983). Such a molecule might be activated by
injections containing factor X, and a modification of the
method of Gordon was therefore used to measure the
procoagulant capacity of cultured Mtln3 cells. We have
previously shown that warfarin treatment of Mtln3 cells
prior to injection into a host animal does not affect their
metastatic behaviour, and this makes it unlikely that CP
plays a major role in the metastatic process in this model.
Direct in vitro analysis of the procoagulant properties of
Mtln3 cells shows that the component of total procoagulant
activity which appears to be dependent on factor X (but not
factor VII) is not predominant, and is unaffected by warfarin
treatment of the cells. These results are similar to those
obtained using non-malignant cell lines, and suggest that
Mtln3 contains little or no CP.
Our previous results, and those of others (Brown, 1973;
McCulloch & George, 1987), suggest that the antimetastatic
effect of warfarin probably occurs within the first few hours
after tumour cells enter the bloodstream. The model we have
adopted allows this part of the metastatic process to be
studied closely, whilst eliminating the influence of changes in
the primary tumour: It has also enabled us to design useful
experiments which would not have been possible in a more
complete model of metastasis. The use of a small number of
cells from a genuinely metastatic neoplasm minimised the
risk, which arises in such models (Poggi et al., 1981) of
artefacts caused by effects of the cell injection on the
coagulation and immune systems, and on the lung
vasculature.
The mechanism by which the factors II, IX and X
complex enhances metastasis cannot be deduced from this
work. Interactions between certain coagulation factors,
notably factor XII and other biological systems such as the
complement system, the kinin system, fibrinolysis and plate-
let activation are known to occur (Zimmerman et al., 1977),
and the metastasis-enhancing effect may be mediated via a
similar mechanism. Our findings must cast doubt on many
of the commonly proposed theories for the interaction of
cancer with coagulation, which have assumed that the inter-
action occurs at the level of fibrin clot formation (Zacharski,
1984). If confirmed by further studies, these results will
require the formulation of quite different theories of the
cancer/coagulation relationship. The finding that intravenous
injection of coagulation factors enhances metastasis may, if
it can be shown to extend to the human situation, have
implications for the current controversy on the effects of
perioperative blood transfusion on survival in cancer
patients.
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